Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

Perspective | Ivermectin is the new Hydroxychorloquine

16 Apr, 2021 | 06:28h | UTC

Ivermectin is the new Hydroxychorloquine – Science-Based Medicine

 

Were pregnant women more affected by COVID-19 in the second wave of the pandemic?

16 Apr, 2021 | 06:24h | UTC

Were pregnant women more affected by COVID-19 in the second wave of the pandemic? – The Lancet

Related: Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis

 

Pandemic Boosts an Old Idea—Bringing Acute Care to the Patient

15 Apr, 2021 | 06:51h | UTC

Pandemic Boosts an Old Idea—Bringing Acute Care to the Patient – JAMA

Related studies: Cohort Study: Selected patients with Covid-19 can be safely discharged on home oxygen, with low mortality and readmission rates AND Association of a Bundled Hospital-at-Home and 30-Day Postacute Transitional Care Program With Clinical Outcomes and Patient Experiences – JAMA Internal Medicine

 

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

15 Apr, 2021 | 07:02h | UTC

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine

Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation

 

New studies suggest SARS-CoV-2 variant B.1.1.7 is not more deadly, just more transmissible

14 Apr, 2021 | 02:12h | UTC

Study 1: Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study – The Lancet Public Health

Study 2: Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study – The Lancet Infectious Diseases

Commentaries: Expert reaction to two papers looking at the transmissibility and severity of the B.1.1.7 variant – Science Media Centre AND UK coronavirus variant not more deadly, just spreads more easily, studies find – LiveScience

 

Study: Protocoled time-limited trials among critically ill patients with advanced medical illnesses were associated with reduction of nonbeneficial ICU treatments

13 Apr, 2021 | 05:16h | UTC

Evaluation of Time-Limited Trials Among Critically Ill Patients With Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments – JAMA Internal Medicine (free for a limited period)

Commentary: Time-Limited Trials and Potentially Nonbeneficial Treatment in the ICU—Willing to Wait for It – JAMA Internal Medicine AND Time-limited trials may decrease the length of stay of critically ill patients in the intensive care unit – 2 Minute Medicine

Author interview: Time-Limited Trials Among Patients With Advanced Illness to Reduce Nonbeneficial ICU Treatments

Related review: Time-limited trial of intensive care treatment: an overview of current literature – Intensive Care Medicine

 

RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19

13 Apr, 2021 | 05:30h | UTC

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19 – PRINCIPLE / University of Oxford

Original study (preprint): Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial – medRxiv

Commentary: Covid: Asthma drug ‘speeds up recovery at home’ – BBC

Related study: Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 (study and commentaries)

 

Cohort Study: Effects of fluoroquinolones on outcomes of patients with aortic dissection or aneurysm

13 Apr, 2021 | 05:05h | UTC

Effects of Fluoroquinolones on Outcomes of Patients With Aortic Dissection or Aneurysm – Journal of the American College of Cardiology

Commentary: Fluoroquinolones Associated With Increased Risk of Aortic Dissection, Aneurysm – American College of Cardiology

Related: Another study suggests fluoroquinolone use may increase the risk of development of aortic aneurysms (study and commentaries) AND Link between fluoroquinolones, aorta problems may not be as strong as thought AND Study: Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation AND FDA Warns About Increased Risk of Aortic Dissection and Ruptures of Aortic Aneurism with Fluoroquinolones AND Meta-analysis: Fluoroquinolones and the Risk of Aortopathy AND Study: Oral Fluoroquinolone and the Risk of Aortic Dissection AND Research: Fluoroquinolone use and risk of aortic aneurysm and dissection

 

AHA/ASA Scientific Statement: Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery

12 Apr, 2021 | 00:50h | UTC

Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery: A Scientific Statement From the American Heart Association/American Stroke Association – Circulation

 

Commentary on Twitter

 

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

13 Apr, 2021 | 05:21h | UTC

Postoperative In-Hospital Morbidity and Mortality of Patients With COVID-19 Infection Compared With Patients Without COVID-19 Infection – JAMA Network Open

Related: Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery AND Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

 

[Press release – not published yet] Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of monoclonal antibodies

13 Apr, 2021 | 05:26h | UTC

Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (Casirivimab with Imdevimab) – Regeneron

Commentaries: Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV – STAT AND Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81% – Endpoint News

 

Another study shows intravenous radiocontrast use is not associated with reduced kidney function

12 Apr, 2021 | 00:44h | UTC

Association of Intravenous Radiocontrast With Kidney Function: A Regression Discontinuity Analysis – JAMA Internal Medicine

Commentaries: Radiocontrast Exposure Safe for Kidney Function – HCP Live AND Exposure to contrast on CTPA doesn’t cause long-term kidney injury – AuntMinnie

Related: ACR/NKF Consensus Statement: “The Risk of Acute Kidney Injury Developing in Patients with Reduced Kidney Function Following Exposure to Intravenous Iodinated Contrast Media has Been Overstated” (Guideline and commentaries)

 

Commentary on Twitter (thread – click for more)

 

M-A: Treatment for bleeding esophageal varices in people with decompensated liver cirrhosis

12 Apr, 2021 | 00:39h | UTC

Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta‐analysis – Cochrane Library

Summary: Treatment for bleeding from enlarged veins in the oesophagus (food pipe) in people with advanced scarring of the liver – Cochrane Library

Related Cochrane Reviews: M-A: Secondary prevention of variceal bleeding in adults with previous esophageal variceal bleeding due to decompensated liver cirrhosis AND Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis – Cochrane Library

 

Comprehensive Review | Pneumonia

9 Apr, 2021 | 03:14h | UTC

Pneumonia – Nature Reviews Disease Primers (free for a limited period)

Try this link if the above is paywalled.

 

Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

12 Apr, 2021 | 01:24h | UTC

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil

9 Apr, 2021 | 03:36h | UTC

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?

9 Apr, 2021 | 03:28h | UTC

Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? – The Lancet Diabetes & Endocrinology

 

The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19

9 Apr, 2021 | 03:35h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 – NIH COVID-19 Treatment Guidelines

 

Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials

8 Apr, 2021 | 08:59h | UTC

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California – JAMA Internal Medicine

Commentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly

 

Commentary on Twitter (thread – Click for more)

 

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

6 Apr, 2021 | 01:12h | UTC

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Summary for Patients: Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians

News release: ACP best practice advice: Shorter course of antibiotics may be appropriate for some common infection – American College of Physicians

 

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

7 Apr, 2021 | 01:48h | UTC

Guidance produced from the Expert Haematology Panel (EHP) focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination – British Society of Haematology

Related: Exceedingly rare side effects reported with AstraZeneca vaccine in the UK – 22 cases of cerebral venous sinus thrombosis with low levels of platelets out of 18 million vaccinated individuals

 

Commentary on Twitter

 

Large study showed no association between blood group types and increased risk of Covid-19

7 Apr, 2021 | 01:41h | UTC

Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population – JAMA Network Open

 

Commentary on Twitter

 

Diagnostic Test Interpretation: Evaluation of Hypokalemia

6 Apr, 2021 | 01:07h | UTC

Evaluation of Hypokalemia – JAMA (free for a limited period)

 

M-A: Colchicine administration for percutaneous coronary intervention

6 Apr, 2021 | 00:58h | UTC

Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

Related: Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials – European Heart Journal (link to abstract – $ for full-text)

 

Cohort Study: Selected patients with Covid-19 can be safely discharged on home oxygen, with low mortality and readmission rates

5 Apr, 2021 | 01:52h | UTC

Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute Care Setting With Supplemental Oxygen – JAMA Network Open

Video: Home Oxygen Instructions for Discharged Patients With COVID-19

Commentaries: Covid-19: Ambulatory Management with Home Oxygen Results in Low Mortality, Low Readmissions – Physician’s Weekly AND Mortality, readmission low with COVID-19 discharge on home oxygen – HealthDay

 

Commentaries on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.